Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response

This study has been terminated.
Advanced Biochemical Compounds GmbH
Information provided by:
Technische Universität Dresden Identifier:
First received: September 13, 2005
Last updated: August 25, 2009
Last verified: August 2009
The purpose of this study is to monitor the amino acid uptake of brain tumors, before and during radiotherapy, with positron emission tomography.

Condition Phase
Brain Tumor
Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response

Further study details as provided by Technische Universität Dresden:

Estimated Enrollment: 40
Study Start Date: December 2003

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
OMFD-PET of all patients after subtotal resection or biopsy of malignant glioma was evaluated.

Inclusion Criteria:

  • Brain tumor
  • Radiation therapy indicated
  • Written consent

Exclusion Criteria:

  • Pregnancy
  • Mental impairment
  • Drug/alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00180193

Department of Nuclear Medicine
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Advanced Biochemical Compounds GmbH
Principal Investigator: Joerg Kotzerke, MD Department of Nuclear Medicine
  More Information

Responsible Party: Prof. Dr. med. Jörg Kotzerke, Klinik und Poliklinik für Nuklearmedizin Identifier: NCT00180193     History of Changes
Other Study ID Numbers: ABX-OMFD-FU
Study First Received: September 13, 2005
Last Updated: August 25, 2009

Keywords provided by Technische Universität Dresden:
F-18-OMFD processed this record on April 28, 2017